Chinese expert consensus on the diagnosis and management of primary mediastinal large B-cell lymphoma(2024)
扫码查看
点击上方二维码区域,可以放大扫码查看
原文链接
NETL
NSTL
维普
万方数据
原发纵隔大B细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBL)是一种起源于纵隔的成熟侵袭性大B细胞淋巴瘤,具有独特的临床、病理及分子学特征.近年来,对PMBL发病机制的认识及治疗均有不同程度的更新,特别是新药治疗领域取得了较大进展.为提高我国临床医师对PMBL的诊断及治疗水平,中华医学会血液学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)淋巴瘤专家委员会组织相关专家组,制订了本共识.
Primary mediastinal large B-cell lymphoma(PMBL)is an aggressive B-cell lymphoma that is thought to arise from thymic(medullary)B cells and has unique clinicopathologic and molecular fea-tures.In recent years,the understanding of the pathogenesis and treatment of PMBL has been updated to varying degrees,particularly in the area of new drug therapy.In order to improve the diagnosis and treat-ment of PMBL in China,the Lymphocyte Disease Group of the Chinese Medical Association(CMA)and the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology(CSCO)commissioned a group of experts to formulate this consensus.